ROCHE: A Heavy Weight to give Substance to your Portfolio

BOSTON (AFX) -- Shares of ChromaVision rocketed out ahead of other
biotechnology stocks in early trading Tuesday after the small company said it
won regulatory clearance for a breast cancer test.
ChromaVision shares soared $2.47, or 200 percent, to $3.70. ChromaVision said
the FDA had approved the company's ACIS system for use in the treatment of
breast cancer patients. The test helps in measuring a protein known as HER2.
Assessing levels of the HER2 protein is important in deciding whether a patient
should be treated with Herceptin, a breast cancer therapy from Genentech .
Overall, biotech stocks were edging lower in early dealings. The Amex
Biotechnology Index dipped 0.5 percent, and the Nasdaq Biotechnology Index
nudged down 0.1 percent.
This story was supplied by CBSMarketWatch. For further information see
www.cbsmarketwatch.com.